Cite
HARVARD Citation
Ray, K. et al. (2023). Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study. Atherosclerosis. pp. 14-21. [Online].